# RAPT Therapeutics, Inc.

RAPT Therapeutics, Inc. is a company headquartered in South San Francisco, CA, United States.

## Company overview

- **Legal name:** RAPT Therapeutics, Inc.
- **Former names in filing history:** RAPT Therapeutics, Inc. (2019-05-24 to 2026-05-15); FLX Bio, Inc. (2016-05-05 to 2019-01-02)
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** South San Francisco, CA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001673772

## About

RAPT Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001673772, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2025-03-06, it reported net income of USD -129,865,000; total assets of USD 240,325,000 for the fiscal period ended 2024-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2024 (period ended 2024-12-31)

- **Net income:** -$129.9M (USD -129,865,000)
- **Total assets:** $240.3M (USD 240,325,000)
- **Cash and equivalents:** $169.7M (USD 169,735,000)
- **Operating cash flow:** -$83.3M (USD -83,297,000)

### FY2023 (period ended 2023-12-31)

- **Revenue:** $0 (USD 0)
- **Net income:** -$116.8M (USD -116,798,000)
- **Total assets:** $173.3M (USD 173,329,000)
- **Cash and equivalents:** $47.5M (USD 47,478,000)
- **Operating cash flow:** -$97.0M (USD -97,048,000)

### FY2022 (period ended 2022-12-31)

- **Revenue:** $1.5M (USD 1,527,000)
- **Net income:** -$83.8M (USD -83,838,000)
- **Total assets:** $266.2M (USD 266,209,000)
- **Cash and equivalents:** $38.9M (USD 38,946,000)
- **Operating cash flow:** -$70.8M (USD -70,771,000)

### FY2021 (period ended 2021-12-31)

- **Revenue:** $3.8M (USD 3,813,000)
- **Net income:** -$69.2M (USD -69,204,000)
- **Total assets:** $198.6M (USD 198,636,000)
- **Cash and equivalents:** $24.0M (USD 24,027,000)
- **Operating cash flow:** -$61.0M (USD -61,026,000)

## Recent SEC filings

- Form 8-K — filed 2026-03-03 — period 2026-03-03 — 8-K
- Form 8-K — filed 2026-01-20 — period 2026-01-19 — 8-K
- Form 8-K — filed 2026-01-14 — period 2026-01-14 — 8-K
- Form 8-K — filed 2025-11-28 — period 2025-11-24 — 8-K
- Form 10-Q — filed 2025-11-06 — period 2025-09-30 — 10-Q
- Form 8-K — filed 2025-11-06 — period 2025-11-06 — 8-K
- Form 8-K — filed 2025-10-23 — period 2025-10-21 — 8-K
- Form 8-K — filed 2025-10-20 — period 2025-10-20 — 8-K
- Form 10-Q — filed 2025-08-07 — period 2025-06-30 — 10-Q
- Form 8-K — filed 2025-08-07 — period 2025-08-07 — 8-K
- Form 8-K — filed 2025-07-08 — period 2025-07-08 — 8-K
- Form 8-K — filed 2025-06-23 — period 2025-06-23 — 8-K

---

Updated: 2026-10-23T19:32:55Z

Canonical page: https://altss.com/profile/rapt-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology